What the Research Says About MOTS-c: A Mitochondrial-Derived Peptide of Growing Scientific Interest

For Research Use Only (RUO). The information below summarizes published preclinical literature and is provided for educational and scientific reference purposes only.

A small peptide with a big role in metabolic research

MOTS-c (Mitochondrial Open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the 12S ribosomal RNA region of the mitochondrial genome. Researchers have become increasingly interested in it because it appears to act not only inside the cell but also as a circulating signaling molecule, with skeletal muscle and adipose tissue identified as primary areas of study. Notably, studies have reported that circulating levels of the peptide tend to decline with age, which has made it a frequent subject in laboratory investigations of metabolism and aging biology.

This post walks through what two peer-reviewed publications have reported about MOTS-c in cell-culture and animal models. None of the findings described here involve approved therapeutic uses, and all observations come from controlled research settings.

Muscle atrophy signaling: findings from cell and mouse models

A 2021 study published in the American Journal of Physiology – Endocrinology and Metabolism examined how MOTS-c relates to myostatin, a protein that acts as a negative regulator of skeletal muscle mass. The research team worked with cultured mouse muscle cells (C2C12 myotubes) and with mice fed a high-fat diet.

Several observations emerged from this preclinical work:

• In a human cohort study referenced within the paper, plasma MOTS-c levels showed an inverse correlation with plasma myostatin levels — meaning higher measured levels of one tended to accompany lower levels of the other.

• In cultured muscle cells exposed to palmitic acid (a saturated fatty acid used to model lipid stress), adding MOTS-c to the culture was associated with preservation of muscle-cell (myotube) number and diameter compared with cells exposed to palmitic acid alone.

• In high-fat-diet-fed mice given MOTS-c, researchers measured lower circulating myostatin and reduced myostatin gene expression in skeletal muscle.

The authors proposed a molecular pathway to explain these laboratory observations, describing a signaling cascade involving CK2, PTEN, mTORC2, AKT, and the transcription factor FOXO1. In their model, changes along this pathway were associated with reduced expression of muscle-wasting–related genes in the animals studied. These are mechanistic findings in cells and rodents and have not been established as effects in humans.

MOTS-c in the broader aging-research conversation

A 2022 review in the International Journal of Molecular Sciences surveyed the wider body of literature on MOTS-c and its proposed biological roles. The review notes that under certain stress conditions, the peptide has been observed to translocate to the cell nucleus, where it has been studied in connection with the regulation of metabolic-response genes.

The review also gathers reports across multiple research areas in which MOTS-c has been investigated, including studies relevant to metabolic balance, muscle homeostasis, and various age-associated conditions examined in laboratory and animal models. As a review article, it compiles and discusses findings from many primary sources rather than reporting new experiments, and it frames MOTS-c as an active area of ongoing scientific investigation rather than an established intervention.

Why this matters to the research community

Taken together, these publications illustrate why MOTS-c has become a recurring subject in metabolic and aging research. The peptide sits at an interesting intersection of mitochondrial biology, cell signaling, and whole-organism physiology, and the published work points to specific, testable molecular pathways that other laboratories can continue to investigate.

For researchers, the practical takeaway is that MOTS-c offers a well-characterized starting point for in vitro and animal studies into mitochondrial signaling and muscle biology — with a documented mechanistic framework already described in the literature to build upon.

Important Compliance Notice

For Research Use Only (RUO). Not for human or veterinary use. Not for use in diagnostic or therapeutic procedures.

Products discussed in connection with this content are intended solely for laboratory research conducted by qualified professionals. This article summarizes published scientific literature for educational purposes and does not constitute medical, health, or therapeutic advice.

The findings described above were observed in cell-culture systems and animal models. They have not been evaluated by the U.S. Food and Drug Administration. Nothing in this article is intended to diagnose, treat, cure, or prevent any disease or health condition in humans or animals, and no statement here should be interpreted as a claim of safety or efficacy for any such use. Any extrapolation of preclinical findings to humans is unsupported and is not endorsed by this content.

Purchasers and users are solely responsible for ensuring their use of any research material complies with all applicable laws, regulations, and institutional guidelines.

References

1. Kumagai H, Coelho AR, Wan J, Mehta HH, Yen K, Huang A, Zempo H, Fuku N, Maeda S, Oliveira PJ, Cohen P, Kim S-J. MOTS-c reduces myostatin and muscle atrophy signaling. American Journal of Physiology – Endocrinology and Metabolism. 2021;320(4)–E690. doi:10.1152/ajpendo.00275.2020. PMCID: PMC8238132. PMID: 33554779.

2. Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. International Journal of Molecular Sciences. 2022;23(19):11991. doi:10.3390/ijms231911991. PMCID: PMC9570330. PMID: 36233287.